Aleksey Ustyugov

Aleksey Ustyugov

Institute of Physiologically Active Compounds of Russian Academy of Sciences - - / Russia
Medical and Health Sciences / Physiology
AD Scientific Index ID: 4409512
Институт физиологически активных соединений Российской академии наук
person_outline Aleksey Ustyugov's MOST POPULAR ARTICLES
1-) Drugs in clinical trials for Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s disease: the major trendsSO Bachurin, EV Bovina, AA UstyugovMedicinal research reviews 37 (5), 1186-1225, 20172872017
2-) Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice*♦TA Shelkovnikova, OM Peters, AV Deykin, N Connor-Robson, ...Journal of biological chemistry 288 (35), 25266-25274, 20131222013
3-) Chronic administration of dimebon ameliorates pathology in Tau P301S transgenic miceOM Peters, N Connor-Robson, VB Sokolov, AY Aksinenko, MS Kukharsky, ...Journal of Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s Disease 33 (4), 1041-1049, 2013752013
4-) Alzheimer\'s disease–future therapy based on dendrimersG Aliev, GM Ashraf, VV Tarasov, VN Chubarev, J Leszek, K Gasiorowski, ...Current Neuropharmacology 17 (3), 288-294, 2019632019
5-) Dimebon slows progression of proteinopathy in γ-synuclein transgenic miceSO Bachurin, TA Shelkovnikova, AA Ustyugov, O Peters, I Khritankova, ...Neurotoxicity research 22, 33-42, 2012582012